Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Nov 23;78(21):2042-2056.
doi: 10.1016/j.jacc.2021.08.073.

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

Patricia Palau  1 , Julia Seller  2 , Eloy Domínguez  3 , Clara Sastre  1 , Jose María Ramón  1 , Rafael de La Espriella  1 , Enrique Santas  1 , Gema Miñana  4 , Vicent Bodí  4 , Juan Sanchis  4 , Alfonso Valle  2 , F Javier Chorro  4 , Pau Llácer  5 , Antoni Bayés-Genís  6 , Julio Núñez  7
Affiliations
Free article
Randomized Controlled Trial

Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

Patricia Palau et al. J Am Coll Cardiol. .
Free article

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Coll Cardiol. 2022 Mar 1;79(8):848. doi: 10.1016/j.jacc.2022.01.012. J Am Coll Cardiol. 2022. PMID: 35210040 No abstract available.

Abstract

Background: Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet β-blockers are commonly used in HFpEF despite the lack of robust evidence.

Objectives: This study aimed to evaluate the effect of β-blocker withdrawal on peak oxygen consumption (peak Vo2) in patients with HFpEF and chronotropic incompetence.

Methods: This is a multicenter, randomized, investigator-blinded, crossover clinical trial consisting of 2 treatment periods of 2 weeks separated by a washout period of 2 weeks. Patients with stable HFpEF, New York Heart Association functional classes II and III, previous treatment with β-blockers, and chronotropic incompetence were first randomized to withdrawing from (arm A: n = 26) versus continuing (arm B: n = 26) β-blocker treatment and were then crossed over to receive the opposite intervention. Changes in peak Vo2 and percentage of predicted peak Vo2 (peak Vo2%) measured at the end of the trial were the primary outcome measures. To account for the paired-data nature of this crossover trial, linear mixed regression analysis was used.

Results: The mean age was 72.6 ± 13.1 years, and most of the patients were women (59.6%) in New York Heart Association functional class II (66.7%). The mean peakVo2 and peak Vo2% were 12.4 ± 2.9 mL/kg/min, and 72.4 ± 17.8%, respectively. No significant baseline differences were found across treatment arms. Peak Vo2 and peak Vo2% increased significantly after β-blocker withdrawal (14.3 vs 12.2 mL/kg/min [Δ +2.1 mL/kg/min]; P < 0.001 and 81.1 vs 69.4% [Δ +11.7%]; P < 0.001, respectively).

Conclusions: β-blocker withdrawal improved maximal functional capacity in patients with HFpEF and chronotropic incompetence. β-blocker use in HFpEF deserves profound re-evaluation. (β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity [PRESERVE-HR]; NCT03871803; 2017-005077-39).

Keywords: HFpEF; chronotropic incompetence; crossover trial; heart rate; peak Vo(2); percentage of predicted peakVo(2); β-blockers.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This work was supported by grants from the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute: Fondos de Investigación Sanitaria (PI17/01426), and cofunded with European Regional Development Fund and Centro de Investigación Biomédica en Red Enfermedades Cardiovascular funds (16/11/00420 and 16/11/00403). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Comment in

Publication types

Substances

Associated data